التفاصيل البيبلوغرافية
| العنوان: |
Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy |
| المؤلفون: |
De Kort, Anna M., Kuiperij, H. Bea, Marques, Tainá M., Jäkel, Lieke, van den Berg, Emma, Kersten, Iris, van Berckel‐Smit, Hugo E. P., Duering, Marco, Stoops, Erik, Abdo, Wilson F., Rasing, Ingeborg, Voigt, Sabine, Koemans, Emma A., Kaushik, Kanishk, Warren, Andrew Davock, Greenberg, Steven M., Brinkmalm, Gunnar, Terwindt, Gisela M., Wermer, Marieke J. H., Schreuder, Floris H. B. M., Klijn, Catharina J. M., Verbeek, Marcel M. |
| المساهمون: |
Eli Lilly and Company, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, National Institutes of Health, Stichting Dioraphte, Teva Pharmaceutical Industries, ZonMw |
| المصدر: |
Annals of Neurology ; volume 93, issue 6, page 1173-1186 ; ISSN 0364-5134 1531-8249 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2023 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
Objective Vascular amyloid β (Aβ) accumulation is the hallmark of cerebral amyloid angiopathy (CAA). The composition of cerebrospinal fluid (CSF) of CAA patients may serve as a diagnostic biomarker of CAA. We studied the diagnostic potential of the peptides Aβ38, Aβ40, Aβ42, and Aβ43 in patients with sporadic CAA (sCAA), hereditary Dutch‐type CAA (D‐CAA), and Alzheimer disease (AD). Methods Aβ peptides were quantified by immunoassays in a discovery group (26 patients with sCAA and 40 controls), a validation group (40 patients with sCAA, 40 patients with AD, and 37 controls), and a group of 22 patients with D‐CAA and 54 controls. To determine the diagnostic accuracy, the area under the curve (AUC) was calculated using a receiver operating characteristic curve with 95% confidence interval (CI). Results We found decreased levels of all Aβ peptides in sCAA patients and D‐CAA patients compared to controls. The difference was most prominent for Aβ42 (AUC of sCAA vs controls for discovery: 0.90, 95% CI = 0.82–0.99; for validation: 0.94, 95% CI = 0.89–0.99) and Aβ43 (AUC of sCAA vs controls for discovery: 0.95, 95% CI = 0.88–1.00; for validation: 0.91, 95% CI = 0.83–1.0). All Aβ peptides except Aβ43 were also decreased in sCAA compared to AD (CSF Aβ38: AUC = 0.82, 95% CI = 0.71–0.93; CSF Aβ40: AUC = 0.88, 95% CI = 0.80–0.96; CSF Aβ42: AUC = 0.79, 95% CI = 0.66–0.92). Interpretation A combined biomarker panel of CSF Aβ38, Aβ40, Aβ42, and Aβ43 has potential to differentiate sCAA from AD and controls, and D‐CAA from controls. ANN NEUROL 2023;93:1173–1186 |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1002/ana.26610 |
| الإتاحة: |
https://doi.org/10.1002/ana.26610Test |
| حقوق: |
http://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.339A4B5B |
| قاعدة البيانات: |
BASE |
